Skip to content Inauguração emGrand opening inInauguración en --d --h --m --s · Cadastro VIP ›· VIP sign-up ›· Registro VIP › Abrimos hoje · aguardeWe open today · hold onAbrimos hoy · aguarde Loja aberta! Entrar ›Store open! Enter ›¡Tienda abierta! Entrar ›
Eagle Pharma
Track order WhatsApp

KNOWLEDGE · COMPOUNDS

Semax

Also known as: ACTH(4-10) analogue

CognitiveClinical trialsPubMed records: 100count from PubMed, not curated
Ask Eagle AI about this compound

Overview

O Semax é um heptapeptídeo análogo sintético do fragmento ACTH(4-10), desenvolvido na Rússia e aprovado para uso clínico na Rússia e Ucrânia. Atua como nootrópico estimulante, elevando BDNF e modulando sistemas dopaminérgico e serotoninérgico, promovendo foco, produtividade e neuroproteção. Original in PT-BR

Semax is catalogued under Cognitive. 24 Eagle articles in this library reference this compound.

Category
Cognitive
Research stage
Clinical trials — Aprovado na Rússia/Ucrânia Original in PT-BR
PubMed records
100 (count from PubMed, not curated)
Eagle articles on this compound
24 Eagle articles

Mechanism

Upregulation de BDNF + modulação dopamina/serotonina — foco e neuroproteção Original in PT-BR

O Semax é um análogo estabilizado do fragmento ACTH(4-10) — Met-Glu-His-Phe-Pro-Gly-Pro — com adição de Pro-Gly-Pro para prolongar meia-vida. Seu mecanismo nootrópico envolve múltiplas vias: (1) Upregulation de BDNF (Brain-Derived Neurotrophic Factor) em hipocampo e córtex — BDNF é o principal fator de crescimento neuronal, essencial para plasticidade sináptica e memória; (2) Modulação do sistema dopaminérgico — aumenta turnover de dopamina, melhorando foco e motivação; (3) Modulação serotoninérgica — efeitos antidepressivos leves; (4) Efeito neuroprotetor — reduz dano oxidativo neuronal e melhora sobrevivência celular em isquemia cerebral. Diferente do ACTH completo, Semax NÃO afeta o eixo adrenal e não eleva cortisol. Original in PT-BR

Eagle articles on this compound

Chemical information

CAS
80714-61-0
Molecular formula
C₃₇H₅₁N₉O₁₀S
Molecular weight
813.93 g/mol
Sequence
MEHFPGP
Amino acids
7 counted from the sequence above
Solubility
Solúvel em água e soluções nasais Original in PT-BR
Stability
Solução nasal: 30 dias a 2-8°C. Liofilizado: estável a -20°C Original in PT-BR
Half-life
~30 minutos (intranasal) Original in PT-BR
Bioavailability
Alta (intranasal — atravessa barreira hematoencefálica) Original in PT-BR
Onset
15-30 minutos (efeito agudo), 5-7 dias (efeitos neuroprotetores) Original in PT-BR
Routes
Intranasal

Research references

No individual dosing recommendation is given. Values are as recorded in the source, with species and route stated where known.

Third-party research score

70/ 100

Score assigned by the imported source, on its own scale and with no published methodology. Eagle does not compute it, does not verify it and does not endorse it. It appears here to preserve the record, not as an assessment.

  • Semax aumentou expressão de BDNF significativamente em modelos experimentais Original in PT-BR

    PMID: 17465043Year: 2007Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • Melhora de performance cognitiva em voluntários saudáveis Original in PT-BR

    PMID: 16996037Year: 2006Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • Redução de dano neuronal e melhora de recuperação funcional pós-AVC Original in PT-BR

    PMID: 11443560Year: 2001Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

Safety

Commonly reported

  • Leve irritação nasal
  • Cefaleia transitória (raro)
  • Insônia se usado à noite

Serious

  • Sem efeitos adversos graves reportados na literatura clínica russa

Contraindications

  • Convulsões/epilepsia (BDNF pode reduzir limiar convulsivo)
  • Transtorno bipolar (risco de mania)
  • Gravidez/amamentação

Warnings

  • Usar apenas pela MANHÃ — propriedades estimulantes
  • Pode potencializar estimulantes (cafeína, anfetaminas)
  • Tolerância possível com uso contínuo — ciclar

Original in PT-BR — This text was written in Brazilian Portuguese and is shown as recorded. Open the PT-BR page for Semax.

Lab tests named in the source

  • Não requer exames específicos
  • Cortisol (confirmar ausência de elevação)

The source names the tests and nothing else: no reference values and no thresholds. None were added here. Interpreting a result is a clinical act and is not offered on this page.

Reported protocols

Recorded in the imported source as community protocols. They are NOT Eagle protocols, were not reviewed by Eagle, and are not a dosing recommendation, a prescription or clinical guidance. Values appear exactly as recorded, in the language they were written in.

Dosing summary as recorded

Dose Padrão
200-600mcg intranasal/dia Original in PT-BR
Frequência
1-2x/dia (manhã / manhã+tarde) Original in PT-BR
Via
Intranasal (spray ou gotas) Original in PT-BR
Timing
Manhã (NUNCA à noite) Original in PT-BR
Ciclo
3-4 semanas ON / 1-2 OFF Original in PT-BR

Vial sizes: 3mg (nasal) — Peptide Calculator

Interactions

These relations come from the imported reference material, which records one label and one comment per pair and no source: no PMID, no population or model, no evidence type and no degree of certainty. Eagle did not verify them and does not endorse them. «Compatible», «Caution» and «Avoid» are the imported material's wording, not an Eagle authorisation or prohibition, and none of this is medical advice.

Reported synergy

  • Selank

    Semax (manhã/foco) + Selank (noite/calma) = yin-yang nootrópico. Mecanismos complementares sem sobreposição Original in PT-BR

Compatible

Caution

  • Dihexa

    Ambos aumentam fatores neurotróficos — redundância potencial e excesso de estimulação Original in PT-BR

Related

View all (24)

← Back to knowledge area